These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
142 related items for PubMed ID: 16421458
1. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Aichhorn W, Marksteiner J, Walch T, Zernig G, Saria A, Kemmler G. Int Clin Psychopharmacol; 2006 Mar; 21(2):81-5. PubMed ID: 16421458 [Abstract] [Full Text] [Related]
2. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. Castberg I, Skogvoll E, Spigset O. J Clin Psychiatry; 2007 Oct; 68(10):1540-5. PubMed ID: 17960969 [Abstract] [Full Text] [Related]
4. Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring. Vella T, Mifsud J. J Pharm Pharmacol; 2014 Jun; 66(6):747-59. PubMed ID: 24392714 [Abstract] [Full Text] [Related]
5. Pharmacokinetics, tolerability, and clinical effectiveness of quetiapine fumarate: an open-label trial in adolescents with psychotic disorders. McConville BJ, Arvanitis LA, Thyrum PT, Yeh C, Wilkinson LA, Chaney RO, Foster KD, Sorter MT, Friedman LM, Brown KL, Heubi JE. J Clin Psychiatry; 2000 Apr; 61(4):252-60. PubMed ID: 10830145 [Abstract] [Full Text] [Related]
6. Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate. Cramer JA, Sernyak M. Clin Ther; 2004 Jun; 26(6):905-14. PubMed ID: 15262461 [Abstract] [Full Text] [Related]
7. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC. J Clin Psychiatry; 2006 May; 67(5):789-97. PubMed ID: 16841629 [Abstract] [Full Text] [Related]
8. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. Winter HR, Earley WR, Hamer-Maansson JE, Davis PC, Smith MA. J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):81-98. PubMed ID: 18294091 [Abstract] [Full Text] [Related]
9. Possible drug-drug interaction between quetiapine and lamotrigine--evidence from a Swedish TDM database. Andersson ML, Björkhem-Bergman L, Lindh JD. Br J Clin Pharmacol; 2011 Jul; 72(1):153-6. PubMed ID: 21651616 [Abstract] [Full Text] [Related]
10. Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine. Atmaca M, Ozdemir H, Cetinkaya S, Parmaksiz S, Belli H, Poyraz AK, Tezcan E, Ogur E. J Psychiatr Res; 2007 Nov; 41(10):821-7. PubMed ID: 16950400 [Abstract] [Full Text] [Related]
11. Open-label steady-state pharmacokinetic drug interaction study on co-administered quetiapine fumarate and divalproex sodium in patients with schizophrenia, schizoaffective disorder, or bipolar disorder. Winter HR, DeVane CL, Figueroa C, Ennis DJ, Hamer-Maansson JE, Davis PC, Smith MA. Hum Psychopharmacol; 2007 Oct; 22(7):469-76. PubMed ID: 17729385 [Abstract] [Full Text] [Related]
14. Quetiapine alone and added to a mood stabilizer for serious mood disorders. Sajatovic M, Brescan DW, Perez DE, DiGiovanni SK, Hattab H, Ray JB, Bingham CR. J Clin Psychiatry; 2001 Sep; 62(9):728-32. PubMed ID: 11681770 [Abstract] [Full Text] [Related]
15. Retrospective Analysis of Steady-State Sodium Valproate Plasma Concentrations in Chinese Patients With Bipolar Disorder: Impact of Demographic and Clinical Characteristics. Qiming Q, Ping Z, Huiqi L, Leyu X, LIren L, Ming L. Ther Drug Monit; 2024 Oct 01; 46(5):658-663. PubMed ID: 38648661 [Abstract] [Full Text] [Related]
16. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study. Mamo DC, Uchida H, Vitcu I, Barsoum P, Gendron A, Goldstein J, Kapur S. J Clin Psychiatry; 2008 Jan 01; 69(1):81-6. PubMed ID: 18312041 [Abstract] [Full Text] [Related]
17. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Gefvert O, Bergström M, Långström B, Lundberg T, Lindström L, Yates R. Psychopharmacology (Berl); 1998 Jan 01; 135(2):119-26. PubMed ID: 9497016 [Abstract] [Full Text] [Related]
18. Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors. Fisher DS, Handley SA, Flanagan RJ, Taylor DM. Ther Drug Monit; 2012 Aug 01; 34(4):415-21. PubMed ID: 22777152 [Abstract] [Full Text] [Related]
19. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. Altamura AC, Mundo E, Dell'Osso B, Tacchini G, Buoli M, Calabrese JR. J Affect Disord; 2008 Sep 01; 110(1-2):135-41. PubMed ID: 18329720 [Abstract] [Full Text] [Related]
20. Single-dose relative bioavailability of a new quetiapine fumarate extended-release formulation: a postprandial, randomized, open-label, two-period crossover study in healthy Uruguayan volunteers. Estevez-Carrizo FE, Parrillo S, Ercoli MC, Estevez-Parrillo FT. Clin Ther; 2011 Jun 01; 33(6):738-45. PubMed ID: 21704238 [Abstract] [Full Text] [Related] Page: [Next] [New Search]